New antibody aims to tame lupus by targeting troublemaking cells
NCT ID NCT07491900
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called HB2198 in 30 adults with moderate to severe lupus, including kidney inflammation. The drug is designed to temporarily remove certain immune cells (B cells) that drive the disease. Participants receive two doses and are monitored for a year to check safety and whether lupus activity improves.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRA-RENAL LUPUS (ERL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site
RECRUITINGBrisbane, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Can engineered immune cells tame stubborn autoimmune diseases?
- Blood traps may reveal lupus kidney treatment success
- A simple blood marker may reveal hidden heart risks in lupus
- Can a gentler steroid dose protect children's kidneys without the harsh side effects?
- Could an Anti-Inflammatory diet ease lupus pain and fatigue?